Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO plus IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227

被引：1
|
作者：
Peters, S. [1 ]
Penrod, J. [2 ]
Li, J. [2 ]
Lubinga, S. [2 ]
Gupta, R. [2 ]
Bushong, J. [2 ]
Rizzo, J. [2 ]
Ramalingam, S. [3 ]
机构：
[1] Lausanne Univ Hosp, Dept Oncol UNIL CHUV, Lausanne, Switzerland
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Emory, Winship Canc Inst, Atlanta, GA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10P
引用
收藏
页码：S32 / S33
页数：2
相关论文
共 50 条
  • [1] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227
    O'Byrne, K. J.
    Lee, K. H.
    Kim, S-W.
    Park, K.
    Nishio, M.
    Sakai, H.
    Ohe, Y.
    Fukuhara, T.
    Kang, J-H.
    Daga, H.
    Yu, C-J.
    Hotta, K.
    Tanaka, H.
    Takeda, M.
    Yokoyama, T.
    Nathan, F. E.
    Lee, J-S.
    ANNALS OF ONCOLOGY, 2020, 31 : S824 - S824
  • [2] Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for metastatic non-small cell lung cancer (mNSCLC): Results from CheckMate 227
    Reck, Martin
    Brahmer, Julie R.
    Lee, Jong-Seok
    Ciuleanu, Tudor-Eliade
    Caro, Reyes Bernabe
    Nishio, Makoto
    Urban, Laszlo
    Audigier-Valette, Clarisse
    Lupinacci, Lorena
    Sangha, Randeep
    Paz-Ares, Luis
    Borghaei, Hossein
    O'byrne, Kenneth John
    Gupta, Ravi G.
    Bushong, Judith
    Li, Li
    Blum, Steven I.
    Eccles, Laura
    Ramalingam, Suresh S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 162 - 162
  • [3] 5-year Survival Data in the First-line (1L) Treatment of advanced non-small cell Lung Cancer (mNSCLC) with Nivolumab (NIVO) plus Ipilimumab (IPI) vs Chemotherapy (chemo): Results of the CheckMate 227 Study
    Jaeschke, B.
    Brahmer, J. R.
    Lee, J. S.
    Ciuleanu, T. E.
    Caro, R. B.
    Nishio, M.
    Urban, L.
    Audigier-Valette, C.
    Lupinacci, L.
    Sangha, R.
    Paz-Ares, L. G.
    Reck, M.
    Borghaei, H.
    O'Byrne, K. J.
    Gupta, R. G.
    Bushong, J.
    Li, L.
    Blum, S. I.
    Eccles, L.
    Ramalingam, S. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 98 - 99
  • [4] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) plus chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA
    John, T.
    Sakai, H.
    Ikeda, S.
    Cheng, Y.
    Kasahara, K.
    Sato, Y.
    Nakahara, Y.
    Takeda, M.
    Kaneda, H.
    Zhang, H.
    Maemondo, M.
    Minato, K.
    Hisada, T.
    Misumi, Y.
    Satouchi, M.
    Hotta, K.
    Li, A.
    Oukessou, A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S847 - S848
  • [5] Nivolumab (nivo) plus ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227
    Hellmann, Matthew D.
    Ciuleanu, Tudor Eliade
    Pluzanski, Adam
    Lee, Jong Seok
    Otterson, Gregory
    Audigier-Valette, Clarisse
    Minenza, Elisa
    Linardou, Helena
    Burgers, Sjaak
    Salman, Pamela
    Borghaei, Hossein
    Ramalingam, Suresh S.
    Brahmer, Julie
    Reck, Martin
    O'Byrne, Kenneth J.
    Geese, William J.
    Green, George
    Chang, Han
    Szustakowski, Joseph D.
    Bhagavatheeswaran, Prabhu
    Healey, Diane
    Fu, Yali
    Nathan, Faith
    Paz-Ares, Luis
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Nivolumab (NIVO) plus ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1
    Ramalingam, S. S.
    Ciuleanu, T. E.
    Pluzanski, A.
    Lee, J. -S.
    Schenker, M.
    Caro, R. B.
    Lee, K. H.
    Zurawski, B.
    Audigier-Valette, C.
    Provencio, M.
    Linardou, H.
    Kim, S. -W.
    Borghaei, H.
    Hellmann, M. D.
    O'Byrne, K. J.
    Paz-Ares, L. G.
    Reck, M.
    Nathan, F. E.
    Brahmer, J. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S2 - S3
  • [7] Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non-small cell lung cancer (NSCLC): Results from CheckMate 227.
    Brahmer, Julie R.
    Lee, Jong-Seok
    Ciuleanu, Tudor-Eliade
    Caro, Reyes Bernabe
    Nishio, Makoto
    Urban, Lazio
    Audigier-Valette, Clarisse
    Lupinacci, Lorena
    Sangha, Randeep S.
    Paz-Ares, Luis G.
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth John
    Gupta, Ravi
    Bushong, Judith
    Li, Li
    Blum, Steven I.
    Eccles, Laura
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [8] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis
    Peters, S.
    Ramalingam, S. S.
    Paz-Ares, L.
    Bernabe Caro, R.
    Zurawski, B.
    Kim, S-W.
    Alexandru, A.
    Lupinacci, L.
    de la Mora Jimenez, E.
    Sakai, H.
    Albert, I.
    Vergnenegre, A.
    Reck, M.
    Borghaei, H.
    Brahmer, J. R.
    O'Byrne, K. J.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Nathan, F. E.
    Hellmann, M. D.
    ANNALS OF ONCOLOGY, 2019, 30 : 913 - +
  • [9] Nivolumab (NIVO) plus ipilimumab (IPI) versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1
    Thomas, M.
    Ramalingam, S. S.
    Ciuleanu, T. E.
    Pluzanski, A.
    Lee, J. -S.
    Schenker, M.
    Bernabe Caro, R.
    Lee, K. H.
    Zurawski, B.
    Audigier-Valette, C.
    Provencio, M.
    Linardou, H.
    Kim, S. -W.
    Borghaei, H.
    Hellmann, M. D.
    O'Byrne, K. J.
    Paz-Ares, L. G.
    Reck, M.
    Nathan, F. E.
    Brahmer, J. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 140 - 141
  • [10] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
    Schumann, C.
    Paz-Ares, L.
    Ciuleanu, T. -E
    Lee, J. -S
    Urban, L.
    Caro, Bernabe R.
    Park, K.
    Sakai, H.
    Ohe, Y.
    Nishio, M.
    Pluzanski, A.
    Ramalingam, S. S.
    Brahmer, J. R.
    Borghaei, H.
    O'Byrne, K. J.
    Hellmann, M. D.
    Memaj, A.
    Bushong, J.
    Tran, P.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 173 - 173
12345